{"disease":{"id":"branch-retinal-vein-occlusion","name":"branch retinal vein occlusion"},"drugs":{"marketed":[{"drug_id":"aflibercept","indication_name":"Branch retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vegf Trap","generic_name":"AFLIBERCEPT","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor","quality_score":55,"revenue":"9800","mechanism":""},{"drug_id":"dexamethasone","indication_name":"Branch retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"eylea","indication_name":"Branch retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Eylea","company_name":"Texas Retina Associates","drug_phase":"marketed","molecular_target":"Placenta growth factor, Vascular endothelial growth factor A, Vascular endothelial growth factor B","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"lucentis","indication_name":"Branch retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lucentis","company_name":"Santen Inc.","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"ranibizumab-nuna","indication_name":"Branch retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BYOOVIZ","generic_name":"RANIBIZUMAB-NUNA","company_name":"SAMSUNG BIOEPIS CO LTD","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":5,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05476926","title":"A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT04740905","title":"A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":553,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT03802630","title":"Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":450,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05520177","title":"A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":351,"lead_sponsor_name":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","has_results":false},{"nct_id":"NCT01976338","title":"Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":283,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03108352","title":"Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein Occlusion","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":255,"lead_sponsor_name":"Chengdu Kanghong Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT04516278","title":"A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":195,"lead_sponsor_name":"Outlook Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07205887","title":"A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"EyeBiotech Ltd.","has_results":false},{"nct_id":"NCT03709745","title":"Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":110,"lead_sponsor_name":"St. Erik Eye Hospital","has_results":false},{"nct_id":"NCT04601688","title":"Branch Retinal Vein Occlusion (BRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"He Eye Hospital","has_results":false},{"nct_id":"NCT03637283","title":"Anti-VEGF Instead of Intraoperative Fan-shaped Photocoagulation in BRVO Combined With Vitreous Hemorrhage","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Wenzhou Medical University","has_results":false},{"nct_id":"NCT03054766","title":"Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for ME Secondary to BRVO","phase":"NA","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Beijing Hospital","has_results":false},{"nct_id":"NCT06146309","title":"Assessment Of Peri-papillary Retinal Nerve Fiber Layer Thickness In Patients With Unilateral Branch Retinal Vein Occlusion","phase":"NA","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Al-Azhar University","has_results":false},{"nct_id":"NCT04667897","title":"601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","has_results":false},{"nct_id":"NCT02953938","title":"Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03405376","title":"Prospective Trial of Treat and Extend Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":49,"lead_sponsor_name":"Yeungnam University College of Medicine","has_results":false},{"nct_id":"NCT03651011","title":"Navigated Laser In Branch Retinal Vein Occlusion Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Odense University Hospital","has_results":false},{"nct_id":"NCT03892434","title":"Bevacizumab Versus DEX Implant Followed by Bevacizumab in ME Secondary to BRVO","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Yeungnam University College of Medicine","has_results":false},{"nct_id":"NCT06664502","title":"A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":38,"lead_sponsor_name":"EyeBiotech Ltd.","has_results":false},{"nct_id":"NCT02503540","title":"Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Justis Ehlers","has_results":true},{"nct_id":"NCT06708624","title":"Ocular Safety and Usability Study for FYB201 PFS","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Formycon AG","has_results":false},{"nct_id":"NCT06708637","title":"Ocular Safety and Usability Study for FYB203 PFS","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Formycon AG","has_results":false},{"nct_id":"NCT05127525","title":"EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"iRenix Medical, Inc.","has_results":false},{"nct_id":"NCT04120636","title":"Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":3,"lead_sponsor_name":"Targeted Therapy Technologies, LLC","has_results":false},{"nct_id":"NCT04120311","title":"Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":2,"lead_sponsor_name":"Targeted Therapy Technologies, LLC","has_results":false}],"total":25},"guidelines":[],"source":"Drug Landscape verified database"}